Journal of Literature Pharmacy Sciences

Bitkisel İlaçların Farmakokinetik-Biyoyararlanım Değerlendirmeleri ve Ruhsat Aşamaları: Geleneksel Derleme
Pharmacokinetics-Bioavailability Assessments and Registration Stages of Herbal Medicines: Traditional Review
Burcu TİMURa,b Zeynep Şafak TEKSİNa
aGazi Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji ABD, Biyofarmasötik ve Farmakokinetik BD, Ankara, Türkiye
bZonguldak Bülent Ecevit Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji ABD, Zonguldak, Türkiye
J Lit Pharm Sci. 2022;11(1):61-76
doi: 10.5336/pharmsci.2021-86561
Article Language: TR
Full Text
ÖZET
Tıbbi değere sahip bitkilerden hareketle üretilen bitkisel ilaç ve geleneksel bitkisel tıbbi ürünlerin kullanımı günümüzde giderek artmaktadır. Bitkisel ilaçlar ve geleneksel bitkisel tıbbi ürünler, konvansiyonel ilaçlarda aranan kalite, etkinlik ve güvenilirlik özelliklerini taşıması ve iyi üretim uygulamaları kurallarına göre üretilmesinin yanı sıra Dünya Sağlık Örgütü tarafından yayımlanan iyi tarım uygulamaları gerekliliklerini de sağlamalıdır. Bitkisel ilaç ve geleneksel tedavide uzun yıllar kullanılan tıbbi bitkilerin güvenilirliği göz önünde bulundurularak ruhsatlandırılan geleneksel bitkisel tıbbi ürünler için standardize edilmiş halde kullanıma sunulmaları, içerik ve etkinliklerinin kanıtlanması, farmakokinetik özelliklerinin ve biyoyararlanımlarının belirlenmesi, doz-cevap ilişkilerinin ortaya konulması, konvansiyonel ilaçlarla olan etkileşimlerinin belirlenmesi oldukça önemli ve gerekli noktalardır. Bazı bitkisel bileşikler, düşük çözünürlük veya permeabilite nedeniyle düşük biyoyararlanıma sahiptir. Düşük biyoyararlanım göstermesi nedeniyle yetersiz terapötik etkinliğe sahip bitkisel bileşiklerin tedaviye kazandırılması için yenilikçi formülasyon yaklaşımları uygulanmakta ve bitkisel bileşiklerin farmakokinetik özellikleri iyileştirilmeye çalışılmaktadır. İlaç taşıyıcı sistemler ile bitkisel bileşiklerin biyoyararlanımlarında belirgin artış gözlenmektedir. Bitkisel ürünler için yasal düzenlemeler ise ülkelere göre farklılık göstermektedir. Türkiye'de bitkisel ürünlerin üretimi ve pazara çıkışıyla ilgili düzenlemeler; Türkiye İlaç ve Tıbbi Cihaz Kurumu ile Gıda, Tarım ve Hayvancılık Bakanlığı mevzuatlarına göre farklı yürütülmektedir. Bu çalışmada, bitkisel bileşiklerin farmakokinetik ve biyoyararlanım özellikleri, bitkisel ürün formülasyonları ve bu ürünlerin ruhsatlandırma aşamaları değerlendirilmiştir.

Anahtar Kelimeler: Bitkisel ilaç; farmakokinetik; biyoyararlanım; dozaj şekilleri; ruhsatlandırma
ABSTRACT
The use of herbal medicine and traditional herbal medicinal products produced from medicinal plants has been increasing day by day. Herbal medicines and traditional herbal medicinal products must ensure to the requirements of good agricultural practice published by the World Health Organization besides they have the quality, efficacy, and safety sought in conventional medicines and produced according to good manufacturing practice. Providing standardized use, proving their content and efficacy, determining their pharmacokinetic properties and bioavailability, revealing dose-response relationships, and determining their interactions with conventional drugs are important and necessary points for herbal medicine and traditional herbal medicinal products that are licensed considering the reliability of medicinal plants used in traditional treatment for many years. Some herbal compounds have poor bioavailability due to low solubility or permeability. For this purpose, innovative formulation approaches have also been applied to bring herbal compounds with insufficient therapeutic activity due to low bioavailability into treatment and the pharmacokinetic properties of herbal compounds have been tried to be improved. Significant enhancement in bioavailability of herbal compounds is observed with drug carrier systems. The legal regulations for herbal products differ in countries. Regulations regarding the production and marketing of herbal products in Turkey are carried out differently according to the regulations of the Turkish Medicines and Medical Devices Agency and the Ministry of Food, Agriculture and Livestock. In this study, pharmacokinetics and bioavailability properties of herbal compounds, herbal products formulations, and registration stages of these products have been evaluated.

Keywords: Herbal medicine; pharmacokinetics; bioavailability; dosage forms; drug registration
REFERENCES:
  1. Orhan IE, Senol Deniz FS. Natural products as potential leads against coronaviruses: could they be encouraging structural models against SARS-CoV-2? Nat Prod Bioprospect. 2020;10(4):171-86. [Crossref]  [PubMed]  [PMC] 
  2. World Health Organization. World Health Organization: Regulatory situation of herbal medicines: a worldwide review. World Health Organization. 1998. [Link] 
  3. Dişli M, Yeşilada E. Türkiye'de bitkisel tıbbi ürünler (Türkiye'de bitkisel ürünlerin standardizasyonu, üretimi ve tağşiş) [Herbal medicinal products in Turkey (Standardization, production and adulteration of herbal products in Turkey)]. J Biotechnol Strateg Health Res. 2019;3 (Özel Sayı):13-21. [Crossref] 
  4. Süzgeç-Selçuk S, Eyisan S. Türkiye'deki eczanelerde bulunan bitkisel ilaçlar [Herbal medicines in the pharmacies in Turkey]. Marmara Pharm J. 2012;16(3):164-80. [Link] 
  5. Sahoo N, Manchikanti P, Dey S. Herbal drugs: standards and regulation. Fitoterapia. 2010; 81(6):462-71. [Crossref]  [PubMed] 
  6. Ersöz T. Bitkisel ilaçlar ve gıda takviyeleri ile ilgili genel yaklaşım ve sorunlar [General approach and problems related to herbal medicines and food supplements]. MİSED Türk Eczacıları Birliği Yayını/Meslek İçi Sürekli Eğitim Dergisi. 2012(27-28):11-21. [Link] 
  7. Busse W. The significance of quality for efficacy and safety of herbal medicinal products. Drug Inf J. 2000;34(1):15-23. [Crossref] 
  8. Steinhoff B. Review: Quality of herbal medicinal products: State of the art of purity assessment. Phytomedicine. 2019;60:153003. [Crossref]  [PubMed] 
  9. Silva RML, Couto AG, Bresolin TMB. Medicinal plants and pharmaceutical technology. In: Cechinel-Filho V, editor. Plant bioactives and drug discovery: principles, practice, and perspectives. 17th ed. New Jersey, USA: John Wiley & Sons; 2012. p.373-7.
  10. Resmî Gazete (6.10.2010, Sayı: 27721) sayılı Geleneksel Bitkisel Tıbbi Ürünler Yönetmeliği; 2010. [Erişim tarihi: 6 Ekim 2021]. Erişim linki: [Link] 
  11. T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu [İnternet]. Copyright © Titck-Türkiye İlaç ve Tıbbi Cihaz Kurumu [Erişim tarihi: 7 Ekim 2021]. Erişim linki: [Link] 
  12. Yılmaz G. Cassia acutifolia-Cassia angustifolia. Demirezer LÖ, editör. FFD Monografları: Tedavide Kullanılan Bitkiler. 1. Baskı. Ankara: MN Medikal & Nobel Tıp Kitabevi; 2011. p.109-12.
  13. Orhan İ. Centella asiatica. Demirezer LÖ, editör. FFD Monografları:Tedavide Kullanılan Bitkiler. 1. Baskı. Ankara: MN Medikal & Nobel Tıp Kitabevi; 2011. p.113-28.
  14. Obodozie OO. Pharmacokinetics and drug interactions of herbal medicines: a missing critical step in the phytomedicine/drug develo pment process. In: Noreddin A, editor. Readings in Advanced Pharmacokinetics-Theory, Methods and Applications. 1st ed. Croatia: InTech; 2012. p.127-58.
  15. He SM, Chan E, Zhou SF. ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr Pharm Des. 2011;17(4):357-407. [Crossref]  [PubMed] 
  16. Mukherjee PK, Harwansh RK, Bhattacharyya S. Bioavailability of herbal products: approach toward improved pharmacokinetics. Mukherjee PK, editor. Evidence-Based Validation of Herbal Medicine. 1st ed. USA: Elsevier; 2015. p.217-45. [Crossref] 
  17. Zhang W, Yang S, He H, Liu C, Chen W, Tang X. Technology for improving the bioavailability of small molecules extracted from traditional Chinese medicines. Expert Opin Drug Deliv. 2009;6(11):1247-59. [Crossref]  [PubMed] 
  18. Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE, et al. Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009;72(2): 471-7. [Crossref]  [PubMed]  [PMC] 
  19. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev. 2003;35(1):35-98. [Crossref]  [PubMed] 
  20. Otake Y, Walle T. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab Dispos. 2002;30(2): 103-5. [Crossref]  [PubMed] 
  21. Hoehle SI, Pfeiffer E, Metzler M. Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases. Mol Nutr Food Res. 2007;51(8):932-8. [Crossref]  [PubMed] 
  22. Pritchett LE, Atherton KM, Mutch E, Ford D. Glucuronidation of the soyabean isoflavones genistein and daidzein by human liver is related to levels of UGT1A1 and UGT1A9 activity and alters isoflavone response in the MCF-7 human breast cancer cell line. J Nutr Biochem. 2008;19(11):739-45. [Crossref]  [PubMed] 
  23. He SM, Li CG, Liu JP, Chan E, Duan W, Zhou SF. Disposition pathways and pharmacokinetics of herbal medicines in humans. Curr Med Chem. 2010;17(33):4072-113. [Crossref]  [PubMed] 
  24. Knaup B, Kahle K, Erk T, Valotis A, Scheppach W, Schreier P, et al. Human intestinal hydrolysis of phenol glycosides - a study with quercetin and p-nitrophenol glycosides using ileostomy fluid. Mol Nutr Food Res. 2007; 51(11):1423-9. [Crossref]  [PubMed] 
  25. Nandhini S, Ilango K. Development and characterization of a nano-drug delivery system containing vasaka phospholipid complex to improve bioavailability using quality by design approach. Res Pharm Sci. 2020;16(1):103-17. [Crossref]  [PubMed]  [PMC] 
  26. Rahman HS, Othman HH, Hammadi NI, Yeap SK, Amin KM, Abdul Samad N, et al. Novel drug delivery systems for loading of natural plant extracts and their biomedical applications. Int J Nanomedicine. 2020;15:2439-83. [Crossref]  [PubMed]  [PMC] 
  27. Karpuz M, Gunay MS, Ozer AY. Liposomes and phytosomes for phytoconstituents. In: Singh M, Singh D, Kanwar J, Chauhan N, eds. Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents. 1st ed. Cambridge, Massachusetts: Academic Press; 2020. p.525-53. [Crossref] 
  28. Khan J, Alexander A, Ajazuddin, Saraf S, Saraf S. Recent advances and future pros pects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives. J Control Release. 2013; 168(1):50-60. [Crossref]  [PubMed] 
  29. Ajazuddin, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010;81(7):680-9. [Crossref]  [PubMed] 
  30. Hatami A. Preparation, description and evaluation of the lethality acid loaded liposomal nanoparticles against in vitro colon and liver cancer. J Chem Rev. 2021;3(2):121-33. [Crossref] 
  31. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. [Crossref]  [PubMed]  [PMC] 
  32. Sogut O, Sezer UA, Sezer S. Liposomal delivery systems for herbal extracts. J Drug Deliv Sci Technol. 2020:102147. [Crossref] 
  33. Alexander A, Ajazuddin, Patel RJ, Saraf S, Saraf S. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release. 2016;241:110-24. [Crossref]  [PubMed] 
  34. Zhang W, Ma W, Zhang J, Song X, Sun W, Fan Y. The immunoregulatory activities of astragalus polysaccharide liposome on mac rophages and dendritic cells. Int J Biol Macromol. 2017;105(Pt 1):852-61. [Crossref]  [PubMed] 
  35. Kumar N, Rai A, Reddy ND, Raj PV, Jain P, Deshpande P, et al. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. Pharmacol Rep. 2014;66(5):788-98. [Crossref]  [PubMed] 
  36. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22-36. [Crossref]  [PubMed] 
  37. Junyaprasert VB, Singhsa P, Suksiriworapong J, Chantasart D. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int J Pharm. 2012; 423(2):303-11. [Crossref]  [PubMed] 
  38. Alam MS, Ahad A, Abidin L, Aqil M, Mir SR, Mujeeb M. Embelin-loaded oral niosomes ameliorate streptozotocin-induced diabetes in Wistar rats. Biomed Pharmacother. 2018; 97:1514-20. [Crossref]  [PubMed] 
  39. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm. 2007;332(1-2):1-16. [Crossref]  [PubMed] 
  40. Modi C, Bharadia P. Transfersomes: new dominants for transdermal drug delivery. Int J Pharmtech Res. 2012;2(3):71-91. [Link] 
  41. Khogta S, Patel J, Barve K, Londhe V. Herbal nano-formulations for topical delivery. J Herb Med. 2020;20:100300. [Crossref] 
  42. Pathan IB, Jaware BP, Shelke S, Ambekar W. Curcumin loaded ethosomes for transdermal application: formulation, optimization, in-vitro and in-vivo study. J Drug Deliv Sci Technol. 2018;44:49-57. [Crossref] 
  43. Marianecci C, Rinaldi F, Mastriota M, Pieretti S, Trapasso E, Paolino D, et al. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release. 2012;164(1): 17-25. [Crossref]  [PubMed] 
  44. Jin Y, Wen J, Garg S, Liu D, Zhou Y, Teng L, et al. Development of a novel niosomal system for oral delivery of Ginkgo biloba extract. Int J Nanomedicine. 2013;8:421-30. [Crossref]  [PubMed]  [PMC] 
  45. Waddad AY, Abbad S, Yu F, Munyendo WL, Wang J, Lv H, et al. Formulation, characterization and pharmacokinetics of Morin hydrate niosomes prepared from various non-ionic surfactants. Int J Pharm. 2013;456(2):446-58. [Crossref]  [PubMed] 
  46. Pando D, Matos M, Gutiérrez G, Pazos C. Formulation of resveratrol entrapped niosomes for topical use. Colloids Surf B Biointerfaces. 2015;128:398-404. [Crossref]  [PubMed] 
  47. Scalia S, Trotta V, Iannuccelli V, Bianchi A. Enhancement of in vivo human skin penetration of resveratrol by chitosan-coated lipid microparticles. Colloids Surf B Biointerfaces. 2015;135:42-9. [Crossref]  [PubMed] 
  48. Scalia S, Haghi M, Losi V, Trotta V, Young PM, Traini D. Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery. Eur J Pharm Sci. 2013;49(2):278-85. [Crossref]  [PubMed]  [PMC] 
  49. Han L, Fu Y, Cole AJ, Liu J, Wang J. Co-encapsulation and sustained-release of four components in ginkgo terpenes from injectable PELGE nanoparticles. Fitoterapia. 2012;83(4):721-31. [Crossref]  [PubMed] 
  50. Xue M, Zhao Y, Li XJ, Jiang ZZ, Zhang L, Liu SH, et al. Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats. Eur J Pharm Sci. 2012;47(4):713-7. [Crossref]  [PubMed] 
  51. Li DC, Zhong XK, Zeng ZP, Jiang JG, Li L, Zhao MM, et al. Application of targeted drug delivery system in Chinese medicine. J Control Release. 2009;138(2):103-12. [Crossref]  [PubMed] 
  52. Yeruva SL, Kumar P, Deepa S, Kondapi AK. Lactoferrin nanoparticles coencapsulated with curcumin and tenofovir improve vaginal defense against HIV-1 infection. Nanomedicine (Lond). 2021;16(7):569-86. [Crossref]  [PubMed] 
  53. Ben-Shabat S, Yarmolinsky L, Porat D, Dahan A. Antiviral effect of phytochemicals from medicinal plants: Applications and drug delivery strategies. Drug Deliv Transl Res. 2020;10(2):354-67. [Crossref]  [PubMed]  [PMC] 
  54. Wu TH, Yen FL, Lin LT, Tsai TR, Lin CC, Cham TM. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm. 2008;346(1-2):160-8. [Crossref]  [PubMed] 
  55. Min KH, Park K, Kim YS, Bae SM, Lee S, Jo HG, et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release. 2008;127(3):208-18. [Crossref]  [PubMed] 
  56. Annamalai A, Christina VL, Sudha D, Kalpana M, Lakshmi PT. Green synthesis, characterization and antimicrobial activity of Au NPs using Euphorbia hirta L. leaf extract. Colloids Surf B Biointerfaces. 2013;108:60-5. [Crossref]  [PubMed] 
  57. Mirza AU, Kareem A, Nami SAA, Khan MS, Rehman S, Bhat SA, et al. Biogenic synthesis of iron oxide nanoparticles using Agrewia optiva and Prunus persica phyto species: Characterization, antibacterial and antioxidant activity. J Photochem Photobiol B. 2018; 185:262-74. [Crossref]  [PubMed] 
  58. Amjad S, Jafri A, Sharma A, Serajuddin M. A novel strategy of nanotized herbal drugs and their delivery in the treatment of diabetes: present status and future prospects. J Herb Med. 2019:100279. [Crossref] 
  59. Vijayakumar S, Vinayagam R, Anand MAV, Venkatachalam K, Saravanakumar K, Wang MH, et al. Green synthesis of gold nanoparticle using eclipta alba and its antidiabetic activities through regulation of Bcl-2 expression in pancreatic cell line. J Drug Deliv Sci Technol. 2020:101786. [Crossref] 
  60. Harwansh RK, Patra KC, Pareta SK. Nanoemulsion as potential vehicles for transdermal delivery of pure phytopharmaceuticals and poorly soluble drug. Int J Drug Deliv. 2011;3(2):209-18. [Link] 
  61. Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med. 2013;65: 117-30. [Crossref]  [PubMed] 
  62. Bhia M, Motallebi M, Abadi B, Zarepour A, Pereira-Silva M, Saremnejad F, et al. Naringenin nano-delivery systems and their therapeutic applications. Pharmaceutics. 2021; 13(2):291. [Crossref]  [PubMed]  [PMC] 
  63. Kassem AA, Abd El-Alim SH, Salman AM, Mohammed MA, Hassan NS, El-Gengaihi SE. Improved hepatoprotective activity of Beta vulgaris L. leaf extract loaded self-nanoemulsifying drug delivery system (SNEDDS): in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2020;46(10):1589-603. [Crossref]  [PubMed] 
  64. Hayati F, Chabib L, Fauzi IS, Awaluddin R, Sumayya, Faizah WS, et al. Effects of Pegagan (Centella asiatica L.) Ethanolic Extract SNEDDS (Self-nanoemulsifying Drug Delivery Systems) on the Development of Zebrafish (Danio rerio) Embryos. J Pharm Bioallied Sci. 2020;12(4):457-61. [Crossref]  [PubMed]  [PMC] 
  65. Zhu JX, Tang D, Feng L, Zheng ZG, Wang RS, Wu AG, et al. Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochlo ride. Drug Dev Ind Pharm. 2013;39(3): 499-506. [Crossref]  [PubMed] 
  66. Chairuk P, Tubtimsri S, Jansakul C, Sriamornsak P, Weerapol Y. Enhancing oral absorption of poorly water-soluble herb (Kaempferia parviflora) extract using self-nanoemulsifying formulation. Pharm Dev Technol. 2020;25(3): 340-50. [Crossref]  [PubMed] 
  67. Zhao L, Zhang L, Meng L, Wang J, Zhai G. Design and evaluation of a self-microemulsifying drug delivery system for apigenin. Drug Dev Ind Pharm. 2013;39(5):662-9. [Crossref]  [PubMed] 
  68. Chouhan N, Mittal V, Kaushik D, Khatkar A, Raina M. Self emulsifying drug delivery system (SEDDS) for phytoconstituents: a review. Curr Drug Deliv. 2015;12(2):244-53. [Crossref]  [PubMed] 
  69. Liu CS, Chen L, Hu YN, Dai JL, Ma B, Tang QF, et al. Self-microemulsifying drug delivery system for ımproved oral delivery and hypnotic efficacy of ferulic acid. Int J Nanomedicine. 2020;15:2059-70. [Crossref]  [PubMed]  [PMC] 
  70. Pal S, Mittapelly N, Husain A, Kushwaha S, Chattopadhyay S, Kumar P, et al. A butanolic fraction from the standardized stem extract of cassia occidentalis l delivered by a self-emulsifying drug delivery system protects rats from glucocorticoid-induced osteopenia and muscle atrophy. Sci Rep. 2020;10(1):1-14. [Crossref]  [PubMed]  [PMC] 
  71. Sermkaew N, Plyduang T. Self-microemulsifying drug delivery systems of Moringa oleifera extract for enhanced dissolution of kaempferol and quercetin. Acta Pharm. 2020;70(1):77-88. [Crossref]  [PubMed] 
  72. Liu W, Tian R, Hu W, Jia Y, Jiang H, Zhang J, et al. Preparation and evaluation of self-microemulsifying drug delivery system of baica lein. Fitoterapia. 2012;83(8):1532-9. [Crossref]  [PubMed] 
  73. Yoo JH, Shanmugam S, Thapa P, Lee ES, Balakrishnan P, Baskaran R, et al. Novel self-nanoemulsifying drug delivery system for enhanced solubility and dissolution of lutein. Arch Pharm Res. 2010;33(3):417-26. [Crossref]  [PubMed] 
  74. Başaran AA. Ülkemizdeki bitkisel İlaçlar ve ürünlerde yasal durum [Legal status of herbal medicines and products in our country]. MİSED Türk Eczacıları Birliği Yayını/Meslek İçi Sürekli Eğitim Dergisi. 2012(27-28):22-6. [Link] 
  75. Qu L, Zou W, Wang Y, Wang M. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States. Phytomedicine. 2018;42:219-25. [Crossref]  [PubMed] 

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com